logo
Share SHARE
FONT-SIZE Plus   Neg

Crosshair Energy Appoints Mark Ludwig As President & CEO

Crosshair Energy Corp. (CXZ,CXX.TO) announced the appointment of Mark Ludwig, as President & Chief Executive Officer effective April 30, 2012 and the appointment of Chris Healey to Crosshair's Board of Directors, effective April 25, 2012.

Ludwig was appointed Chief Operating Officer in July 2011 and brings more than 30 years of mining, management and mineral exploration and development experience to his new role. Ludwig takes over from Stewart Wallis, who is retiring from his role as President & CEO but will remain as a member of Crosshair's Board of Directors and a consultant to Crosshair as well as the entire Forbes West group of companies.

Prior to joining Crosshair, Ludwig was the Vice President of Operations of Neutron Energy. From 2005 to 2008 he was employed by Hecla Mining Company as a Senior Mining Engineer/Project Manager and later as Manager of Corporate Development. From 1984 until 2005 he worked in various positions with BHP Billiton including as a Senior Project and Mining Engineer. Mr. Ludwig will continue to be based in Denver, Colorado.

Healey will be taking over the Board seat vacated by Ian Smith, who is retiring as a director of Crosshair.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Automakers on Monday reported strong U.S. vehicle sales for the month of July, driven by continued demand for trucks and sport-utility vehicles amid an improving economy, lower gas prices and easy availability of credit. Detroit's Big Three - General Motors Co., Ford Motor Co. and FCA US, LLC - all reported vehicle sales above analyst expectations. British lender Lloyds Banking Group Plc. Friday reported higher profit in its first half, benefited by increased net interest income and margin as well as lower impairment. Looking ahead, the company lifted its net interest margin forecast. Amgen reported an increase in second-quarter profit, driven by sales of arthritis drug Enbrel and osteoporosis treatments Xgeva and Prolia, and improved margins. Both earnings and sales topped Wall Street estimates.
comments powered by Disqus
Follow RTT